Search Browse Earnings

Voyager Therapeutics, Inc.

Nasdaq:VYGR

Biological Products, (No Diagnostic Substances)·LEXINGTON, MA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Voyager Therapeutics, Inc. — SlamSEC

Revenue

$250.0M

+511.2% YoY

FY 2025

Adj. EBITDA

$126.5M

50.6% margin

FY 2025

Net Income

$132.3M

52.9% margin

FY 2025

EPS (Diluted)

$2.97

FY 2025

Stock Price

$5.00

+28.2%

2026-03-10

52W Range

$2.65 – $5.55

P/E Ratio

1.7x

Market Cap

$298.0M

Cash

$71.4M

FY 2025

Total Debt

—

Net Cash

$71.4M

FY 2025

Enterprise Value

$226.6M

Debt / EBITDA

-0.6x

FY 2025

EV / EBITDA

1.8x

Employees

—

CEO

Sandrock Alfred

CFO

Jorgensen Nathan D.